High Triglycerides Signal Hidden Heart Risk, but Effective Treatments Remain Limited

November 16, 2026
High Triglycerides Signal Hidden Heart Risk, but Effective Treatments Remain Limited
  • The International Atherosclerosis Society consensus describes hypertriglyceridaemia as an underdiagnosed and undertreated marker of residual cardiovascular risk, driven mainly by cholesterol carried in triglyceride-rich remnant particles—not by triglyceride molecules themselves.

  • The condition affects an estimated 29% of adults worldwide and more than 40% in Latin America, yet INTERASPIRE data show just 2% of patients with elevated triglycerides were receiving triglyceride-specific medication.

  • The consensus classifies triglyceride levels below 150 mg/dL as normal and levels of 500 mg/dL or higher as severe, with the latter carrying a high risk of acute pancreatitis; clinicians should also investigate lifestyle, medications, genetic factors, and secondary conditions such as insulin resistance, endocrine disorders, and metabolic dysfunction-associated steatotic liver disease.

  • Because high triglycerides can make LDL-cholesterol estimates unreliable, the consensus recommends assessing non-HDL cholesterol, apolipoprotein B, and remnant cholesterol to better gauge atherogenic particles and residual risk.

  • Randomized trials have not established that lowering triglycerides itself reduces major cardiovascular events, so elevated levels should prompt broader assessment and management of atherosclerotic risk.

  • When lipid-lowering treatment is needed, statins are the priority because they reduce cardiovascular risk and LDL cholesterol while typically lowering triglycerides by 10%–30% and helping clear remnant particles.

  • Lifestyle changes are central: the consensus recommends regular aerobic and strength exercise, cutting excess calories, refined sugars, simple carbohydrates, and saturated fats, and eating more vegetables, legumes, and fish; losing 5%–10% of body weight can lower triglycerides by about 20%.

  • For severe hypertriglyceridaemia, strict alcohol abstinence and a very-low-fat diet are recommended to reduce pancreatitis risk.

  • Fibrates are not recommended for primary cardiovascular risk reduction in patients with mild-to-moderate hypertriglyceridaemia who are already taking statins, based on trials including ACCORD and PROMINENT; they may be considered in severe cases to lower triglycerides, although evidence that they prevent pancreatitis is limited.

  • The consensus discourages over-the-counter fish oil supplements, and trials of combined DHA and EPA have not shown cardiovascular benefit; purified EPA, or icosapent ethyl, may be considered for selected high-risk patients, though the REDUCE-IT mineral-oil placebo has prompted debate and treatment can raise atrial fibrillation and bleeding risks.

  • ApoC-III-targeting therapies olezarsen and plozasiran have reduced triglycerides and acute pancreatitis incidence and have received approval for familial chylomicronaemia syndrome, while ANGPTL3-targeting drugs and FGF21 analogues remain under investigation.

  • The consensus calls gene-silencing therapies a major advance for severe disease, but says effective drug strategies to address residual cardiovascular risk in mild-to-moderate hypertriglyceridaemia remain an unmet need.

Summary based on 1 source


Get a daily email with more Science stories

Source

More Stories